Complete dosing of children aged 5 to 11 in two Phase 3 CASGEVY studies
Deadline passed; outcome being checked
- Announced
- 10 Feb 2025
- Due
- 31 Dec 2025
- Status
- Checking
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“expects to complete dosing of this age group in 2025”
What we found
The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 10 Feb 2025
Deadline 31 Dec 2025 (“in 2025”) · wording expected
-
Version 2 · stated 4 Aug 2025
Deadline 31 Dec 2025 (“in the second half of 2025”) · wording firm
“is on track to complete dosing in the second half of 2025.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Dosing of children aged 5-11 in CASGEVY Phase 3 studies
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-VRTX-006546 · Corrections policy